stoxline Quote Chart Rank Option Currency Glossary
  
Inhibikase Therapeutics, Inc. (IKT)
2.355  0.025 (1.07%)    02-06 11:01
Open: 2.35
High: 2.46
Volume: 44,905
  
Pre. Close: 2.33
Low: 2.295
Market Cap: 163(M)
Technical analysis
2025-02-06 10:48:48 AM
Short term     
Mid term     
Targets 6-month :  3.36 1-year :  4.07
Resists First :  2.88 Second :  3.49
Pivot price 2.55
Supports First :  1.89 Second :  1.58
MAs MA(5) :  2.27 MA(20) :  2.62
MA(100) :  2.39 MA(250) :  1.99
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  39.7 D(3) :  33.8
RSI RSI(14): 41.8
52-week High :  4.19 Low :  1.12
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IKT ] has closed above bottom band by 34.0%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.34 - 2.35 2.35 - 2.36
Low: 2.17 - 2.18 2.18 - 2.19
Close: 2.31 - 2.33 2.33 - 2.35
Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Headline News

Fri, 31 Jan 2025
Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St

Wed, 29 Jan 2025
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - Investing.com

Thu, 14 Nov 2024
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewswire

Thu, 24 Oct 2024
Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey

Wed, 23 Oct 2024
Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance

Mon, 21 Oct 2024
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 69 (M)
Held by Insiders 1.7e+006 (%)
Held by Institutions 10.4 (%)
Shares Short 44 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.898e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -23 %
Return on Assets (ttm) 885 %
Return on Equity (ttm) -76.3 %
Qtrly Rev. Growth 79570 %
Gross Profit (p.s.) 0
Sales Per Share -133.66
EBITDA (p.s.) -1.06964e+007
Qtrly Earnings Growth -3.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 1.49
Stock Dividends
Dividend 0
Forward Dividend 187950
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android